MAPK7 and neoplasm: In this context, combination therapy using the ERK5 inhibitor XMD8-92 together with 5-FU was shown to significantly enhance apoptosis and impair tumor growth, compared to either treatment alone, attesting to the potential of this dual therapeutic approach in a preclinical setting.